Oscar Tahuahua, Medical Oncology Fellow at National Cancer Institute(Mexico), shared a post on X:
“Post-hoc Ph3 trial Pretreatment Emotional Distress in adv. Melanoma was linked to lower ORR with TIL Tx (37% vs 69%) & 2y PFS (16% vs 35%). A modifiable factor that may reduce immunotherapy efficacy, underscoring the stress-immune-cancer axis.”
Read the full article here.
More about Immunotherapy for Melanoma on OncoDaily.